“Growing evidence suggests that the endocannabinoid system is involved in the pathogenesis of Alzheimer’s disease (AD) and atherosclerosis.
The purpose of this study was to investigate the activation of the endocannabinoid system in AD in vivo and the possible intermediate role of atherosclerosis…
AD patients present high plasma 2-AG levels, also in relation to heart ischemic disease and cerebral leukoaraiosis.
This may be a protective mechanism hindering neurodegeneration, but it may also play an ambivalent role on cerebrovascular circulation.
The increase in 2-AG and PEA levels observed with ongoing pathological processes may differently modulate cognitive performances.”